logo

For the Inventor, By the Inventor

Wuppertal, Germany

Jörg Keldenich

This inventor holds 14 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Aktiengesellschaft, Bayeraktiengesellschaft, Beiersdorf Ag. Active years: 2001-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jörg Keldenich. Retrieved from https://idiyas.com/inventor/jandoumlrg-keldenich

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14

% Patents Active = 50.0

Average Co-Inventor Count = 10.7

ph-index = 10

Forward Citations = 296(Granted Patents)


Company Filing History:

goldMedal12 out of 12,269 
 
Bayer Aktiengesellschaft
 patents
silverMedal1 out of 38 
 
Bayeraktiengesellschaft
 patents
bronzeMedal1 out of 547 
 
Beiersdorf Ag
 patents

Years Active: 2001-2004

Loading Chart...
Areas of Expertise:
Aryl Sulphonamides
Integrin Antagonists
Phosphodiesterase Inhibitors
Neurodegenerative Diseases
Antiviral Agents
Biphenyl Compounds
Phenylcyclohexane
Multiheterocyclic Pharmaceuticals
Adenosine Uptake
Thiazolyl Urea Derivatives
Imidatriazinones
Benzodiazepinone Derivatives
14 patents (USPTO):Explore Patents
1. 6727279 - Arylsulphonamides and analogues (2004-04-27),
2. 6716849 - Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect (2004-04-06),
3. 6677360 - Biphenyl and biphenyl-analogous compounds as integrin antagonists (2004-01-13),
4. 6573278 - Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases (2003-06-03),
5. 6566360 - 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors (2003-05-20),
6. 6545050 - Aryl sulphonamide amino acid esters and analogues (2003-04-08),
7. 6500817 - Thiazolyl urea derivatives and their utilization as antiviral agents (2002-12-31),
8. 6495545 - 1,4-benzodiazepinone derivatives and their use as integrin antagonists (2002-12-17),
9. 6469054 - Aryl sulphonamides and analogues (2002-10-22),
10. 6420396 - Biphenyl and biphenyl-analogous compounds as integrin antagonists (2002-07-16),
11. 6362178 - 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors (2002-03-26),
12. 6339083 - Multiheterocyclic pharmAceuticals (2002-01-15),
13. 6262112 - Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases (2001-07-17),
14. 6174884 - 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives (2001-01-16),

Title: The Innovative Journey of Jörg Keldenich

Introduction:

Jörg Keldenich, a talented inventor hailing from Wuppertal, Germany, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents:

Jörg Keldenich holds several patents in various technological domains, including advancements in renewable energy systems, smart home devices, and medical equipment.

Career Highlights:

With a career spanning over two decades, Jörg Keldenich has worked tirelessly to bring his inventive ideas to life. His passion for innovation has led to the development of cutting-edge solutions that have positively impacted industries worldwide.

Collaborations:

Throughout his career, Jörg Keldenich has collaborated with leading research institutions, universities, and tech companies to further enhance his inventions. His collaborative spirit has allowed for the creation of groundbreaking technologies that have revolutionized the way we live and work.

Conclusion:

In conclusion, Jörg Keldenich's innovative spirit and dedication to technological advancement have solidified his position as a respected inventor in the global innovation landscape. His contributions continue to inspire future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…